Closing Out the Santa Monica Molecular Markers Program: Two

[Guest LCSC Info]

Closing Out the Santa Monica Molecular Markers Program: Two Final Podcasts

June 7th, 2012 - by Dr. Jack West

http://blog.lungevity.org/2012/06/07/sm ... s-pts-5-6/

Here are the last two podcasts from our program on Molecular Markers in Advanced NSCLC with Drs. Charlie Rudin from Johns Hopkins, Alice Shaw from Massachusetts General Hospital, David Spigel from Sarah Cannon Cancer Center, and Glen Goss from the University of Ottawa. In the first of these two podcasts, Dr. Spigel describes both the benefits and the challenges as we strive to transition from an “all comers” approach to a focus on specific, often molecularly-defined patient populations. His presentation is followed by additional panel discussion that delves into how this transition has disrupted our traditional mindset for clinical research, as well as how this work is beginning to challenge some of our most longstanding beliefs.

Here are the audio and video podcasts, accompanied by the transcript and figures.

Spigel on Molecular Markers in Clinical Trials SM Pt 5 Video Podcast

Spigel on Molecular Markers in Clinical Trials SM Pt 5 Audio Podcast

Spigel on Molecular Markers in Clinical Trials SM Pt 5 Transcript

Spigel on Molecular Markers in Clinical Trials SM Pt 5 Figs

In the last program, Dr. Goss discusses the efforts at incorporating molecular marker studies in lung cancer beyond academic centers and implementing their use across entire health care systems. He presents some work on early pilot efforts, as well as the limitations, including cost issues, while raising the possibility that more refined treatment plans might also ultimately be cost-effective by administering only more effective therapies.

This presentation by Dr. Goss is followed by panel coverage of the questions of what role physicians should play in considering costs of health care recommendations, whether we should be doing “reflex testing” automatically for all patients with advanced NSCLC (or a defined subset), and whether there’s an anticipated immediate value in doing repeat biopsies in one person over the course of ongoing treatment.

The audio and video versions of the podcast, along with transcript and figures, are below.

Goss on Molecular Markers in HC Systems SM Part 6 Video Podcast

Goss on Molecular Markers in HC Systems SM Part 6 Audio Podcast

Goss on Molecular Markers in HC Systems SM Part 6 Transcript

Goss on Molecular Markers in HC Systems SM Part 6 Figs

I hope you find this series of podcasts from this special activity to be helpful and interesting.

In the coming weeks, we’ll turn to a discussion of some of the highlights from ASCO, as well as the next set of podcasts on immunotherapies in lung cancer.